Showing results (211-220 of 442) with videos related to
Sort By:
Pageof 45
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 7, 2009
Effect of ambient air pollution on the incidence of appendicitisGilaad G Kaplan, Elijah Dixon, Remo Panaccione, et al.BMC Gastroenterology|September 5, 2012
Postoperative complications following colectomy for ulcerative colitis: a validation studyChristopher Ma, Marcelo Crespin, Marie-Claude Proulx, et al.Inflammatory Bowel Diseases|October 8, 2013
Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patientsAito Ueno, Humberto Jijon, Ronald Chan, et al.Therapeutic Advances in Gastroenterology|April 2, 2026
Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based studyStephanie Coward, Karen J B Martins, Scott Klarenbach, et al.Gastroenterology|February 12, 2014
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitisRemo Panaccione, Subrata Ghosh, Stephen Middleton, et al.Journal of Crohn'S & Colitis|December 9, 2023
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 StudiesJean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, et al.The American Journal of Gastroenterology|June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid RegistryGeert DʼHaens, Walter Reinisch, Remo Panaccione, et al.Annals of Internal Medicine|May 2, 2007
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialWilliam J Sandborn, Paul Rutgeerts, Robert Enns, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2020
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or UstekinumabAnne Hu, Paulo Gustavo Kotze, Alice Burgevin, et al.Inflammatory Bowel Diseases|May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trialRemo Panaccione, William J Sandborn, Glenn L Gordon, et al.Pageof 45